{"id":"double-blind-esomeprazole","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Headache"},{"rate":"10-15%","effect":"Diarrhea"},{"rate":"7-10%","effect":"Nausea"},{"rate":"5-8%","effect":"Abdominal pain"},{"rate":"3-5%","effect":"Constipation"},{"rate":"3-5%","effect":"Flatulence"}]},"_chembl":{"chemblId":"CHEMBL5314366","moleculeType":"Small molecule","molecularWeight":"769.20"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Esomeprazole is the active S-enantiomer of omeprazole. It irreversibly inhibits the proton pump (H+/K+-ATPase) on the secretory surface of gastric parietal cells, reducing both basal and stimulated gastric acid production. This mechanism provides rapid and sustained acid suppression, making it effective for treating acid-related gastrointestinal disorders.","oneSentence":"Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:49.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of NSAID-induced ulcers"}]},"trialDetails":[{"nctId":"NCT07182890","phase":"PHASE4","title":"Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-09-20","conditions":"Functional Dyspepsia, Probiotics, Depression","enrollment":180},{"nctId":"NCT07187492","phase":"PHASE4","title":"Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-09-20","conditions":"Functional Dyspepsia, Probiotics, Depression","enrollment":180},{"nctId":"NCT07268820","phase":"PHASE4","title":"Heartburn, Gastroesophageal Reflux Disease","status":"RECRUITING","sponsor":"Incheon St.Mary's Hospital","startDate":"2025-07-07","conditions":"GERD","enrollment":160},{"nctId":"NCT05845645","phase":"PHASE1","title":"A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2023-05-31","conditions":"Healthy Study Participants","enrollment":73},{"nctId":"NCT06213818","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2024-03-14","conditions":"Healthy Participants","enrollment":137},{"nctId":"NCT04448028","phase":"PHASE4","title":"Stop of Proton-pump Inhibitor Treatment in Patients With Liver Cirrhosis - a Double-blind, Placebo-controlled Trial","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-04-22","conditions":"Liver Cirrhosis","enrollment":476},{"nctId":"NCT06850480","phase":"PHASE3","title":"A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis","status":"RECRUITING","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2024-12-05","conditions":"Reflux Esophagitis (RE)","enrollment":356},{"nctId":"NCT06783257","phase":"PHASE2","title":"Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding","status":"NOT_YET_RECRUITING","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02","conditions":"Peptic Ulcer Bleeding","enrollment":150},{"nctId":"NCT06720610","phase":"PHASE4","title":"Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis","status":"NOT_YET_RECRUITING","sponsor":"Indonesia University","startDate":"2024-12-09","conditions":"Erosive Esophagitis","enrollment":216},{"nctId":"NCT06162949","phase":"PHASE3","title":"Vonoprazan for Helicobacter Pylori Eradication in Adolescents","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":"Treatment Effectiveness","enrollment":242},{"nctId":"NCT05443984","phase":"PHASE3","title":"JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis","status":"COMPLETED","sponsor":"Onconic Therapeutics Inc.","startDate":"2022-01-17","conditions":"Erosive Esophagitis","enrollment":300},{"nctId":"NCT06526455","phase":"PHASE4","title":"Efficacy and Safety of Vonorasan Versus Esomeprazole in the Treatment of Ulcers After Endoscopic Submucosal Dissection","status":"NOT_YET_RECRUITING","sponsor":"Shicai Ye","startDate":"2024-08-01","conditions":"Ulcers, Gastric","enrollment":196},{"nctId":"NCT01216293","phase":"PHASE1","title":"Effect of Dexlansoprazole on Bone Homeostasis","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-11-01","conditions":"Homeostasis, Bone and Bones","enrollment":115},{"nctId":"NCT05577468","phase":"PHASE3","title":"Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-10-30","conditions":"Helicobacter Pylori Infection","enrollment":561},{"nctId":"NCT06088316","phase":"PHASE4","title":"Efficacy of Amoxicillin-Esomeprazole HDDT Compared to Levofloxacin Triple Therapy for H. Pylori Eradication: A RCT","status":"UNKNOWN","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-02-10","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Eradication","enrollment":70},{"nctId":"NCT04198363","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-04-30","conditions":"Helicobacter Pylori","enrollment":510},{"nctId":"NCT04753437","phase":"PHASE1","title":"A Study of Vonoprazan in Adults With Helicobacter Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-04-06","conditions":"Helicobacter Pylori","enrollment":44},{"nctId":"NCT05701540","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn","status":"UNKNOWN","sponsor":"HK inno.N Corporation","startDate":"2023-03-24","conditions":"Gastroesophageal Reflux Disease","enrollment":338},{"nctId":"NCT02476097","phase":"PHASE4","title":"PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms","status":"UNKNOWN","sponsor":"Victoria Rollason","startDate":"2015-06","conditions":"Stomach Diseases","enrollment":58},{"nctId":"NCT05662514","phase":"NA","title":"Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-02-15","conditions":"Helicobacter Pylori Infection, Gut Microbiota","enrollment":100},{"nctId":"NCT04282954","phase":"PHASE2","title":"Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Onconic Therapeutics Inc.","startDate":"2019-11-15","conditions":"GERD","enrollment":188},{"nctId":"NCT04309916","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2020-05-22","conditions":"Erosive Reflux Disease","enrollment":46},{"nctId":"NCT03967886","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of YYD601 in NERD Patients","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2019-04-10","conditions":"Non-erosive Reflux Disease","enrollment":170},{"nctId":"NCT03943992","phase":"PHASE3","title":"Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)","status":"COMPLETED","sponsor":"Yooyoung Pharmaceutical Co., Ltd.","startDate":"2019-01-29","conditions":"Erosive Esophagitis","enrollment":170},{"nctId":"NCT04769583","phase":"PHASE4","title":"14-day Quadruple Therapy Versus Triple Therapy in HP Eradication","status":"COMPLETED","sponsor":"mohamed bouchoucha","startDate":"2019-02-10","conditions":"Gastritis H Pylori","enrollment":121},{"nctId":"NCT03213639","phase":"PHASE2, PHASE3","title":"Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial)","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-03-15","conditions":"Preeclampsia","enrollment":205},{"nctId":"NCT04080726","phase":"PHASE3","title":"Efficacy and Safety of HIP1601 Capsule","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-10-25","conditions":"Erosive Gastroesophageal Reflux Disease","enrollment":213},{"nctId":"NCT03488147","phase":"PHASE2","title":"Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery","status":"WITHDRAWN","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-07","conditions":"Dysphagia, GERD, Degenerative Joint Disease","enrollment":""},{"nctId":"NCT03736369","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2018-12-13","conditions":"Erosive Esophagitis","enrollment":263},{"nctId":"NCT03184324","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2017-08-28","conditions":"Erosive Gastroesophageal Reflux Disease","enrollment":211},{"nctId":"NCT04407832","phase":"NA","title":"Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy","status":"WITHDRAWN","sponsor":"Changhua Christian Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Bleeding","enrollment":""},{"nctId":"NCT03615677","phase":"PHASE3","title":"Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2018-10-24","conditions":"Erosive Esophagitis (EE)","enrollment":261},{"nctId":"NCT02743949","phase":"PHASE2","title":"Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-07-14","conditions":"Gastroesophageal Reflux","enrollment":256},{"nctId":"NCT03928470","phase":"PHASE4","title":"Clinical Trial to Evaluate the Efficacy and Safety of EsoDuo Tab. 20/800mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2019-01-29","conditions":"Non-erosive Reflux Disease(NERD)","enrollment":379},{"nctId":"NCT02637557","phase":"PHASE2","title":"A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Ironwood Pharmaceuticals, Inc.","startDate":"2016-03-01","conditions":"Gastroesophageal Reflux Disease","enrollment":282},{"nctId":"NCT00745849","phase":"NA","title":"Efficacy of Esomeprazole for Non-Allergic Rhinitis: A Double-blind, Placebo Controlled Trial","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2005-06","conditions":"Vasomotor Rhinitis","enrollment":43},{"nctId":"NCT01670552","phase":"PHASE3","title":"Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients","status":"COMPLETED","sponsor":"EMS","startDate":"2016-02-17","conditions":"Acute and Chronic Inflammation, Dyspepsia","enrollment":490},{"nctId":"NCT03717701","phase":"NA","title":"Metformin and Esomeprazole in Treatment of Early Onset Preeclampsia","status":"UNKNOWN","sponsor":"Aswan University Hospital","startDate":"2018-12-01","conditions":"Pre-Eclampsia","enrollment":120},{"nctId":"NCT03717740","phase":"PHASE3","title":"Esomeprazole for the Prevention of Preeclampsia","status":"UNKNOWN","sponsor":"Aswan University Hospital","startDate":"2018-12-01","conditions":"Pre-Eclampsia","enrollment":1000},{"nctId":"NCT03722433","phase":"PHASE4","title":"Probiotics in the Reduction of Adverse Effects and Dysbiosis of H. Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2018-08-29","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT02959255","phase":"PHASE4","title":"10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2017-01-30","conditions":"Helicobacter Pylori Infection","enrollment":364},{"nctId":"NCT00222079","phase":"NA","title":"Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy","status":"TERMINATED","sponsor":"Douglas Trask","startDate":"2004-11","conditions":"Gastro-esophageal Reflux","enrollment":40},{"nctId":"NCT03006874","phase":"PHASE3","title":"Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2016-05-02","conditions":"Erosive Esophagitis","enrollment":302},{"nctId":"NCT02757144","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2016-03","conditions":"Healthy","enrollment":120},{"nctId":"NCT02708355","phase":"PHASE4","title":"Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-01","conditions":"Heartburn","enrollment":55},{"nctId":"NCT02157376","phase":"PHASE3","title":"Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07","conditions":"Stress Ulcer Prophylaxis","enrollment":343},{"nctId":"NCT00405119","phase":"PHASE2","title":"A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"Gastroesophageal Reflux Disease, Reflux, Gastroesophageal","enrollment":92},{"nctId":"NCT00153660","phase":"PHASE3","title":"Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2005-06","conditions":"Arthritis, Cardiovascular Diseases, Cerebrovascular Disorders","enrollment":514},{"nctId":"NCT02456935","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2015-05","conditions":"Erosive Esophagitis","enrollment":280},{"nctId":"NCT00361985","phase":"PHASE4","title":"Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery","status":"WITHDRAWN","sponsor":"Weill Medical College of Cornell University","startDate":"2008-01","conditions":"Anastomotic Stricture, Morbid Obesity","enrollment":""},{"nctId":"NCT02860624","phase":"PHASE3","title":"Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients","status":"COMPLETED","sponsor":"Livzon Pharmaceutical Group Inc.","startDate":"2011-12","conditions":"Gastroesophageal Reflux Disease","enrollment":550},{"nctId":"NCT01888549","phase":"NA","title":"Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2012-02","conditions":"Chronic Cough Caused by Gastroesophageal Reflux","enrollment":48},{"nctId":"NCT00658632","phase":"PHASE3","title":"Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-02","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":1397},{"nctId":"NCT01757275","phase":"PHASE3","title":"High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-02","conditions":"Bleeding Peptic Ulcer","enrollment":239},{"nctId":"NCT02134405","phase":"PHASE4","title":"Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2014-08","conditions":"Dyspepsia","enrollment":200},{"nctId":"NCT00658528","phase":"PHASE3","title":"Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-02","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":1061},{"nctId":"NCT00658775","phase":"PHASE3","title":"Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2008-02","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":1069},{"nctId":"NCT01669811","phase":"PHASE3","title":"Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-08","conditions":"Refractory Reflux Esophagitis","enrollment":1398},{"nctId":"NCT00881413","phase":"PHASE4","title":"Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding","status":"WITHDRAWN","sponsor":"Lotung Poh-Ai Hospital","startDate":"","conditions":"Peptic Ulcer","enrollment":""},{"nctId":"NCT02355236","phase":"PHASE4","title":"Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis","status":"UNKNOWN","sponsor":"Severance Hospital","startDate":"2015-02","conditions":"Osteoarthritis","enrollment":106},{"nctId":"NCT00660660","phase":"PHASE4","title":"Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Gastroesophageal Reflux Disease","enrollment":276},{"nctId":"NCT00564330","phase":"PHASE1, PHASE2","title":"In Vivo Quantification of Dental Demineralisation Using OCT With and Without Esomeprazole","status":"COMPLETED","sponsor":"Brain-Gut Research Group","startDate":"2007-11","conditions":"Tooth Erosion","enrollment":30},{"nctId":"NCT02028663","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2013-05","conditions":"Erosive Esophagitis, GERD","enrollment":206},{"nctId":"NCT02197143","phase":"PHASE4","title":"A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2013-03","conditions":"Dyspepsia","enrollment":286},{"nctId":"NCT01007019","phase":"PHASE1","title":"Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2009-11","conditions":"Healthy","enrollment":134},{"nctId":"NCT01750437","phase":"PHASE2","title":"Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2013-01","conditions":"Non-erosive Reflux Disease","enrollment":149},{"nctId":"NCT01538849","phase":"PHASE2","title":"Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2012-12","conditions":"Reflux Esophagitis","enrollment":154},{"nctId":"NCT00474903","phase":"PHASE2","title":"Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-04","conditions":"Barrett Esophagus, Esophageal Cancer","enrollment":122},{"nctId":"NCT00317044","phase":"PHASE2","title":"Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-04","conditions":"Asthma, GERD","enrollment":961},{"nctId":"NCT00468559","phase":"PHASE3","title":"Phase 3/Safety & Efficacy of Esomeprazole in Infants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-04","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":98},{"nctId":"NCT02141698","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Dose Finding Study","enrollment":73},{"nctId":"NCT01370538","phase":"PHASE3","title":"Efficacy of Esomeprazole in Patients With Frequent Heartburn","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Heartburn","enrollment":341},{"nctId":"NCT01473173","phase":"PHASE1","title":"Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2011-11","conditions":"Healthy","enrollment":59},{"nctId":"NCT01370525","phase":"PHASE3","title":"Efficacy of Esomeprazole in Patients With Frequent Heartburn","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Heartburn","enrollment":340},{"nctId":"NCT01142128","phase":"PHASE1","title":"Viokase 16, Viokase16 Plus Nexium and Nexium Alone","status":"TERMINATED","sponsor":"University of Florida","startDate":"2009-02","conditions":"Chronic Pancreatitis","enrollment":12},{"nctId":"NCT00206284","phase":"PHASE2","title":"A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"GERD Without Erosive Esophagitis","enrollment":1400},{"nctId":"NCT00206245","phase":"PHASE2","title":"A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"GERD With Erosive Esophagitis","enrollment":1400},{"nctId":"NCT01069939","phase":"PHASE3","title":"Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-02","conditions":"Prevention","enrollment":427},{"nctId":"NCT00699426","phase":"PHASE3","title":"The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Lise Tarnow","startDate":"2008-06","conditions":"Type 2 Diabetes","enrollment":41},{"nctId":"NCT01059383","phase":"PHASE2","title":"Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms","status":"COMPLETED","sponsor":"Vecta Ltd.","startDate":"2009-12","conditions":"Gastroesophageal Reflux","enrollment":52},{"nctId":"NCT00441727","phase":"PHASE3","title":"Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-02","conditions":"Gastric Ulcer, Duodenal Ulcer","enrollment":2426},{"nctId":"NCT01132638","phase":"PHASE3","title":"Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-08","conditions":"GERD","enrollment":713},{"nctId":"NCT00978159","phase":"PHASE4","title":"Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia","status":"UNKNOWN","sponsor":"Ruttonjee Hospital","startDate":"2009-09","conditions":"Aspirin, Dyspepsia","enrollment":128},{"nctId":"NCT00664560","phase":"PHASE3","title":"Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-04","conditions":"Osteoarthritis","enrollment":614},{"nctId":"NCT00287339","phase":"PHASE4","title":"The Utility of Nexium in Chronic Cough and Reflux Disease","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2005-09","conditions":"Cough, GERD","enrollment":40},{"nctId":"NCT00665431","phase":"PHASE3","title":"Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"POZEN","startDate":"2008-04","conditions":"Osteoarthritis","enrollment":610},{"nctId":"NCT00355615","phase":"PHASE3","title":"PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-07","conditions":"Familial Hypercholesterolemia","enrollment":173},{"nctId":"NCT00641004","phase":"PHASE4","title":"Randomized Double-Blind Clinical Trial of Rebamipide vs Esomeprazole in the Treatment of NSAID-induced Gastropathy","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical, Inc., Philippines","startDate":"2008-04","conditions":"NSAID Induced Gastropathy","enrollment":30},{"nctId":"NCT01275937","phase":"PHASE4","title":"A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy","status":"UNKNOWN","sponsor":"Taipei Medical University","startDate":"2011-08","conditions":"Upper Gastrointestinal Bleeding","enrollment":65},{"nctId":"NCT00730665","phase":"PHASE2","title":"Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-01","conditions":"Gastroesophageal Reflux Disease","enrollment":81},{"nctId":"NCT00251979","phase":"PHASE3","title":"A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Gastrointestinal Hemorrhage","enrollment":1312},{"nctId":"NCT00628667","phase":"PHASE4","title":"Chronic Posterior Laryngitis With Suspected Laryngopharyngeal Reflux","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-02","conditions":"Chronic Posterior Laryngitis (CPL)","enrollment":120},{"nctId":"NCT00637559","phase":"PHASE4","title":"Barrett's Esophagus - 315 - 3 Way Cross-Over","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-03","conditions":"Barrett's Esophagus","enrollment":50},{"nctId":"NCT00251992","phase":"PHASE3","title":"Nexium Dyspepsia/AST","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-12","conditions":"Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia","enrollment":1200},{"nctId":"NCT00251901","phase":"PHASE3","title":"Chest Pain Pilot Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"Chest Pain, Gastroesophageal Reflux","enrollment":600},{"nctId":"NCT00251914","phase":"PHASE3","title":"Nexium Dyspepsia/AST","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-12","conditions":"Gastrointestinal Disease, Signs and Symptoms, Digestive, Dyspepsia","enrollment":1500},{"nctId":"NCT00637845","phase":"PHASE4","title":"Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-06","conditions":"Heartburn, Gastroesophageal Reflux Disease","enrollment":248},{"nctId":"NCT01129011","phase":"PHASE3","title":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","status":"COMPLETED","sponsor":"POZEN","startDate":"2007-09","conditions":"Gastric Ulcer","enrollment":420},{"nctId":"NCT00527787","phase":"PHASE3","title":"Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","status":"COMPLETED","sponsor":"POZEN","startDate":"2007-09","conditions":"Gastric Ulcer","enrollment":434},{"nctId":"NCT00633932","phase":"PHASE3","title":"Reflux Esophagitis Phase III Study (Initial Treatment)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-12","conditions":"Reflux Esophagitis","enrollment":602}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":241,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Double Blind Esomeprazole","genericName":"Double Blind Esomeprazole","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by blocking the H+/K+-ATPase enzyme in the stomach's parietal cells. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}